Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity
about
sameAs
Neurobiological investigations into the role of cholecystokinin in panic disorderStructure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptorsInhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolismCharacterization of the binding of a novel radioligand to CCKB/gastrin receptors in membranes from rat cerebral cortexPharmacological analysis of CCK2 receptor antagonists using isolated rat stomach ECL cellsEnhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic ratsPharmacological profile of TP-680, a new cholecystokininA receptor antagonistAbsence of the cholecystokinin-A receptor deteriorates homeostasis of body temperature in response to changes in ambient temperatureElevated cholecystokininergic tone constitutes an important molecular/neuronal mechanism for the expression of anxiety in the mouse.The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsRole of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models.PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexesDose ranging study of the effects of cholecystokinin in healthy volunteersTherapeutic and chemical developments of cholecystokinin receptor ligands.Neuronal network of panic disorder: the role of the neuropeptide cholecystokinin.Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat.The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.CI988, a selective antagonist of cholecystokininB receptors, prevents morphine tolerance in the rat.The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist.Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potentialA two-step strategy to enhance activity of low potency peptides.Increased cholecystokinin labeling in the hippocampus of a mouse model of epilepsy maps to spines and glutamatergic terminals.CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells.Requirement of phospholipase C and protein kinase C in cholecystokinin-mediated facilitation of NMDA channel function and anxiety-like behavior.Mediation by CCKB receptors of the CCK-evoked hyperaemia in rat gastric mucosa.Cholecystokinin antagonists--a toxicologic perspective.Structure-based design in drug discovery--the application of a peptoid drug design strategy for the development of non-peptide neuropeptide receptor ligands.Inter- and intraspecies polymorphisms in the cholecystokinin-B/gastrin receptor alter drug efficacy.Regulation by the neuropeptide cholecystokinin (CCK-8S) of protein phosphorylation in the neostriatumPurification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreasCCKB/gastrin receptor antagonists: recent advances and potential uses in gastric secretory disordersAn important role for cholecystokinin, a CLOCK target gene, in the development and treatment of manic-like behaviors.Evidence for an involvement of the brain cholecystokinin B receptor in anxietyModulatory role of serotonin on feeding behavior.The cholecystokinin hypothesis of panic and anxiety disorders: a review.Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy.Cholecystokinin activates CCKB-receptor-mediated Ca-signaling in hippocampal astrocytes.The role of gastrin and cholecystokinin in normal and neoplastic gastrointestinal growth.
P2860
Q24535665-4B233CB0-0271-4BB7-8475-19412B7EBE6CQ24548810-4F01E848-32D3-46E4-820C-4D88A7DAAFECQ24552584-DB1CFFF7-35D0-4952-AE8D-865764A1D5C3Q24674564-E76F1CBF-C827-44CB-A291-895BA9A4B0B5Q28343282-C37A4B97-E2D1-4AEB-98F8-18BCB4FB0E44Q28343413-6313E554-792D-44ED-A161-FE33AAD0F377Q28363867-CD4D39E4-A5FF-45C9-905D-D9A24CCA2EC8Q28379012-9CB57E73-6720-47E2-9C79-20468ADEE854Q28568778-B63A8669-9BB2-4F2B-9A88-C0D661031BD3Q30476895-34F3506A-0FE4-4205-ABD3-96F1EC307E87Q30486707-C848F486-BD39-43DE-9FA1-C0078581B9CBQ30487910-5C2FCC73-F92E-49DF-80C2-BBE0210DFDECQ30532041-307271CE-1B99-419B-9E7D-B09DE1C6199DQ33792380-2D7AEDC9-9B69-48F5-94E2-319C31C0D988Q33920881-12D07137-1DF7-4A49-BCEE-4F0E36D3246CQ33924027-140E1FC9-B0FA-46E9-910F-7DBD25FFC949Q34272451-BE81C9AC-F0AD-4561-B9C9-47EB605F16D1Q34377960-A2A9D62E-F5C8-49D9-8939-B905D27C135BQ34420283-0285FC88-A8CC-47D2-A0C4-0BD00B6EDFF4Q34466681-8EAECC8A-6D17-4BC5-A41A-10B32C283127Q34550349-8AC18F8C-D42A-46DE-A708-7751F1CC15FDQ34712671-CCF005F2-79AA-4657-B93E-2770C3D3A69DQ35414793-34822F0E-5640-4679-B71B-FC87B4219459Q35713133-861DEF03-9FB2-4A26-A1F4-CB811699BF70Q35778685-C58E50E6-D8B8-4D54-BF81-993B07B5EF6CQ35785604-80955CF7-23C0-49B8-BC02-726DDFBA09ABQ35872825-D5BC9396-3B4C-4880-954C-23A4E64B2F27Q36071597-7E011EF1-C019-4814-87C4-147A9F986DF6Q36179745-911C435F-8A78-46AB-A517-FCDE91B934A5Q36605997-0583D97D-DBB9-4ED2-A2C0-972C50F879D0Q36699381-EBB484C1-533E-46C4-B482-5424D2E15707Q36939596-D517AED9-0FAC-4CEA-8451-A4383447FF5CQ36987633-A9775D25-A0F7-4B3B-A8C1-68F4DE98540EQ37198810-C0CF77B2-182B-426B-A75B-2ED0D7499255Q37395948-5EC741A5-0BFF-49AB-8BDD-E3E29A911E97Q37805802-A1BDE38C-8A00-47B4-B236-A3D315AD5B0AQ37980110-D61B5F60-3C47-4878-86D3-3B26033B2D78Q39378866-E186426E-B789-4D9A-816D-9F44B62F9C6DQ39454110-4D13D097-B8C4-4AF1-A794-3994EEAF36E0Q40548301-45C63145-CB4E-4FCB-B469-98AA9CF193B5
P2860
Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity
description
1990 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
article publié dans les Procee ...... f the United States of America
@fr
artículu científicu espublizáu en 1990
@ast
im September 1990 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: September 1990)
@en
vedecký článok (publikovaný 1990-09)
@sk
vědecký článek publikovaný v roce 1990
@cs
wetenschappelijk artikel (gepubliceerd in 1990-09)
@nl
наукова стаття, опублікована у вересні 1990
@uk
name
Development of a class of sele ...... ing potent anxiolytic activity
@ast
Development of a class of sele ...... ing potent anxiolytic activity
@en
Development of a class of sele ...... ing potent anxiolytic activity
@nl
type
label
Development of a class of sele ...... ing potent anxiolytic activity
@ast
Development of a class of sele ...... ing potent anxiolytic activity
@en
Development of a class of sele ...... ing potent anxiolytic activity
@nl
prefLabel
Development of a class of sele ...... ing potent anxiolytic activity
@ast
Development of a class of sele ...... ing potent anxiolytic activity
@en
Development of a class of sele ...... ing potent anxiolytic activity
@nl
P2093
P2860
P356
P1476
Development of a class of sele ...... ing potent anxiolytic activity
@en
P2093
D C Horwell
G N Woodruff
J C Hunter
R D Pinnock
P2860
P304
P356
10.1073/PNAS.87.17.6728
P407
P577
1990-09-01T00:00:00Z